Last reviewed · How we verify
dapagliflozine
At a glance
| Generic name | dapagliflozine |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Finerenone Plus SGLT2 Inhibitors in Heart Failure (PHASE4)
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
- The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats (PHASE4)
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. (PHASE1)
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria (PHASE2)
- Proteinuria in Renal Transplant Patients Treated with Dapagliflozin (NA)
- Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy (NA)
- Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dapagliflozine CI brief — competitive landscape report
- dapagliflozine updates RSS · CI watch RSS
- Mansoura University portfolio CI